Abstract
Overview
Introduction
The antidyslipidemics market is driven by the statins, which account for 87% of it. However, as many statins are expected to face patent expiry in the coming decade their role is expected to change from a driver to that of almost a resistor. Manufacturers are looking to novel products to protect their franchise, such as Pfizer's atorvastatin/torcetrapib.
Scope
- Country specific event-driven sales forecasts for the period 2005-14 for the US, Japan, France, Germany, Italy, Spain and the UK and Global overview
- Patient potential and prescribing trends overview in the antidyslipidemics market, based on historical sales data and future key events
- Profiles of the country and market-specific issues which will impact future sales, including generic erosion and class switching
- Case studies presenting Pfizer's strategy with atorvastatin/torcetrapib to maintain the Lipitor franchize, and the impact of key clinical trials
Report Highlights
Increased knowledge of the metabolic syndrome, fears of statin side effects, and the increasing data on the importance of HDL have all served to drive growth of the adjunctive anti-dyslipidemic agent market, by creating an opportunity for novel as well as combination therapies.
Pfizer's atorvastatin + torcetrapib combination is expected to have a major impact on the dyslipidemia market and is expected to compete with both atorvastatin and Vytorin (simvastatin + ezetimibe). While Astra -Zeneca's Crestor is set to significantly increase in sales due to new safety data.
The expiration of key statin patents could lead to the shrinking of the market value. The situation will be salvaged by the growing classes of cholesterol uptake inhibitors and single pill combinations.
Reasons to Purchase
- View independent, event-driven forecasts for key anti-dyslipidemic products and classes across the seven major markets
- Obtain key opinion leader comments on various topics including prescribing trends and opinions on currently marketed and late stage development drugs
- Identify the potential impact of clinical trial results, EU healthcare reform and new product launches on the antidyslipidemic market
Table of Contents
- About the Cardiovascular pharmaceutical analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the dyslipidemia market
- CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition for this report
- Current market situation
- National markets
- The statin market
- Lipitor - the global market leader
- Crestor - fastest-growing statin
- Combination therapy
- Vytorin
- The fibrate market
- TriCor/Lypanthyl (fenofibrate)
- The cholesterol uptake inhibitor market
- Zetia
- The nicotinic acid derivatives
- Niaspan
- The ion exchange resins
- The other antidyslipidemics market
- Omega-3 oils
- Probucol, Benflourex and Colesevelam
- CHAPTER 3 COUNTRY MARKET ASSESSMENTS
- Current and future opportunities and threats in the antidyslipidemic
market
- Global opportunities and threats
- Opportunities
- Threats
- Patent expiry and generic erosion
- Global opportunities and threats
- US: opportunities and threats
- Market overview
- Opportunities
- Threats
- Market overview
- Japan: opportunities and threats
- Market overview
- Opportunities
- Threats
- Market overview
- France: opportunities and threats
- Market overview
- Opportunities
- Threats
- Market overview
- Germany: opportunities and threats
- Market overview
- Opportunities
- Threats
- Market overview
- Italy: opportunities and threats
- Market overview
- Opportunities
- Threats
- Market overview
- Spain: opportunities and threats
- Market overview
- Opportunities
- Threats
- Market overview
- UK: opportunities and threats
- Market overview
- Opportunities
- Threats
- Market overview
- Summary of environmental issues affecting the antidyslipidemic market size
- Current and future opportunities and threats in the antidyslipidemic
market
- CHAPTER 4 FORECAST ANALYSIS
- Assumptions and events
- Trial results
- ASCOT
- INTER HEART
- Trial results
- New product launches
- Atorvastatin + torcetrapib
- Livalo
- Forecasts
- Assumptions and events
- CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES
- Pfizer's franchise rotation strategies: a means of protecting brand
revenue
- Lipitor: Pfizer's biggest success
- Lipitor: sales are forecast to plummet in the next decade
- Atorvastatin + torcetrapib: will this FDC be Pfizer's next blockbuster?
- Caduet (atorvastatin + amlodipine): a winning combination?
- Implications of two recent trials
- IDEAL TRIAL: implications
- Japanese MEGA trial
- Pfizer's franchise rotation strategies: a means of protecting brand
revenue
- APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS
- Statin market data
- Lipitor
- Zocor
- Pravachol
- Crestor
- Vytorin
- Fibrate market data
- Lipanthyl/Tricor
- Cedur/Bezatol
- Cholesterol uptake inhibitors
- Zetia
- Nicotinic acid derivatives
- Niaspan
- Ion exchange resins
- Questran
- Other antidyslipidemics
- WelChol
- Statin market data
- APPENDIX B
- Bibliography
- Epidemiology
- Clinical trial data
- Datamonitor
- Other research articles
- Press releases
- Websites
- Report methodology
- Japan sales data
- Key opinion leaders
- Bibliography
- APPENDIX C - MARKET FORECAST DATA
- US forecasts
- Japan forecasts
- France forecasts
- Germany forecasts
- Italy forecasts
- Spain forecasts
- UK forecasts
- M5EU forecasts
- Global forecasts
- About Datamonitor
- About Datamonitor Healthcare
- About the Cardiovascular analysis team
- Disclaimer
- List of Tables
- Table 1: Key players in the antidyslipidemic market
- Table 2: Global sales of the antidyslipidemic drug classes, 2004
- Table 3: Global sales of the branded and generic statins, 2004
- Table 4: Global sales of the branded and generic fibrates, 2004
- Table 5: Sales of Zetia in each market, 2004
- Table 6: Global sales the nicotinic acid derivatives, 2004
- Table 7: Global sales of the ion exchange resins, 2004
- Table 8: Global sales of omega-3 oils, 2004
- Table 9: Global combined Sales of Probucol, Benflourex and Colesevelam, 2004
- Table 10: US antidyslipidemic market data, 2004
- Table 11: Japan antidyslipidemic market data
- Table 12: France antidyslipidemic market data
- Table 13: Germany antidyslipidemic market data
- Table 14: Italy antidyslipidemic market data
- Table 15: Drivers and resistors for genericization in the Italian pharmaceutical market
- Table 16: Spain antidyslipidemic market data
- Table 17: UK antidyslipidemic market
- Table 18: Year of patent expiries of major brands
- Table 19: Lipitor: key facts
- Table 20: Zocor: key facts
- Table 21: Pravachol: key facts
- Table 22: Crestor: key facts
- Table 23: Vytorin: key facts
- Table 24: Lipanthyl/Tricor: key facts
- Table 25: Cedur/Bezatol: key facts
- Table 26: Zetia: key facts
- Table 27: Niaspan: key facts
- Table 28: Questran: key facts
- Table 29: WelChol: key facts
- Table 30: US forecasts to 2014, in $ millions
- Table 31: Japan forecasts to 2014, in $ millions
- Table 32: France forecasts to 2014, in $ millions
- Table 33: Germany forecasts to 2014, in $ millions
- Table 34: Italy forecasts to 2014, in $ millions
- Table 35: Spain forecasts to 2014, in $ millions
- Table 36: UK forecasts to 2014, in $ millions
- Table 37: EU markets forecasts to 2014, in $ millions
- Table 38: Global forecasts to 2014, in $ millions
- List of Figures
- Figure 1: Share of the antidyslipidemic market represented by each of the seven major markets 2004
- Figure 2: Global sales of the antidyslipidemic drug classes
- Figure 3: Proportion of overall drug-treated dyslipidemia patients receiving combination therapy in the seven major markets, 2005
- Figure 4: Percentage of the population over 65 in 2005 (value shown) and a forecast for the next and 10 and 20 years.
- Figure 5: Percentage of men and women over the age of 45 & 55 respectively, in the general population.
- Figure 6: Annual US sales of the antidyslipidemic drug classes
- Figure 7: Annual US sales of the drug classes excluding the statins
- Figure 8: 2004 sales of the statin brands in Japan
- Figure 9: Annual Japanese sales of the antidyslipidemic classes
- Figure 10: Contribution of the three key sources to the Japanese healthcare system, 2001
- Figure 11: Annual French sales of the antidyslipidemic drug classes
- Figure 12: Antidyslipidemics sales in Germany ($m), including statins, 2001-04
- Figure 13: Antidyslipidemics sales in Germany ($m), excluding statins, 2001-04
- Figure 14: Annual Italian sales of the antidyslipidemic drug classes
- Figure 15: Annual sales of the antidyslipidemic classes
- Figure 16: Annual Spanish sales of the antidyslipidemic drug classes excluding the statins
- Figure 17: Annual sales of the antidyslipidemic drug classes
- Figure 18: Annual sales of the antidyslipidemic drug classes
- Figure 19: Summary of environmental issues
